Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to do a Salesforce stock analysis and discuss the risks and upside potential of CRM stock.

1 extracted signal · 1 resolved · 0 still active

The Patient Investor profile imageThe Patient Investor22 Oct 2025, 22:41 UTC
Video preview for Friends! In this video, I'm going to do a Salesforce stock analysis and discuss the risks and upside potential of CRM stock.
Signals
1
Eligible signals in this source
Open
0
Still being tracked
Resolved
1
Evaluable outcomes
Successful
0
Canonical correct result
Failed
1
Canonical failed result
Resolved success
0%
Open and excluded signals omitted
Source overview

AI-generated source summary

Salesforce (CRM) has shown a recent upward trend, breaking out of a prior downtrend. The stock is currently trading around $254.28. The analysis suggests a bullish outlook, with a potential target price of $260.00. A break below $250.00 would invalidate this bullish setup. The company's financial performance, particularly its revenue growth and improving operating margins, are cited as supporting factors. Despite past concerns about share buybacks and stock-based compensation, the current market perception appears to be shifting positively, driven by the company's focus on AI and reaccelerating growth.

AI-generated summary based on the source content.

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. Source processing completed

    Source analysis and structured extraction completed.

  6. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  7. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Extracted intelligence

Signals in this source

Continue the evidence trail
Analyst history

The Patient Investor

Tracked signals
292
Historical success
32.9%
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.